Bristol-Myers to acquire Adnexus for $430M

Bristol-Myers Squibb Co. said it will purchase biotech firm Adnexus Therapeutics for $430 million and up to $75 million in additional conditional payments, to help develop its class of drugs, called Adnectins, and expand the firm's investment in biologics. "We feel biologics will be a cornerstone of our future growth," a Bristol-Myers executive said.

View Full Article in:

Boston Globe (tiered subscription model), The · San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC